By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a


SEARCH JOBS


Industry
Biotechnology


Collaborations

Sunesis Pharmaceuticals, Inc.  Inflammatory and Autoimmune Diseases

Entelos, Inc. 





Company News
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Scientists Uncover Previously Unknown Role for Class of Molecules 8/4/2011 2:52:19 PM
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA): In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding 4/5/2011 8:43:59 AM
Isogenica Limited Announces Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) 3/22/2011 10:37:52 AM
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study 8/31/2010 10:07:02 AM
New Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Diabetes Drug, Canagliflozin Effective in Mid-Stage Study 6/28/2010 6:38:09 AM
WuXi PharmaTech Co., Ltd. Enters into Collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC (CA), a division of Janssen Pharmaceutica for Preclinical Services and Training 3/2/2010 8:43:07 AM
FDA Approves Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8/3/2009 7:45:20 AM
PPD, Inc. (PPDI) Confirms Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) Completion of Additional Phase III Studies Providing Expanded Safety and Efficacy Data for Priligy 6/10/2009 7:07:24 AM
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain 5/7/2009 12:10:39 PM
Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Announces FDA Filings for Paliperidone Palmitate and INVEGA(R) 2/6/2009 8:31:36 AM
123456789
//-->